VERASTEM INC

Verastem insider sales reveal routine tax‑covering moves, not a market shift. Explore how the CEO’s modest sale impacts valuation and the company’s KRAS pipeline.

Verastem insider trading: CEO Dan Paterson’s recent sale shows routine liquidity management, not distress, amid positive momentum and breakthrough‑therapy hopes.

Verastem insider trading: Dan Paterson’s modest share sales reflect a “cash‑in‑advance” strategy amid early‑stage drug development and promising clinical data, offering investors insight into executive liquidity decisions and future growth prospects.

Verastem insider option exercise signals confidence amid market volatility: explore the strategic shift, clinical prospects, and investor impact.